Your latest cannabis business info from Europe

Your latest cannabis business info from Europe


Aleafia Health investments in Europe

As we may know, Europe is a high potential market for North American companies. Many international companies have launched their subsidiaries in Europe, looking at this emerging market. A Canadian cannabis company recently signed a new deal in Europe’s largest and most profitable medical cannabis market. This time it is Aleafia Health that starts new investments in Europe.

Detailing Aleafia growth and achievements

What is the journey of Aleafia Health so far? The portfolio of Aleafia Health seems to be exceptional in the sector. Patients can choose from a variety of goods, including flower, pre-rolls, vapes, edibles, and topicals. Its in-house brands, including Divvy, Emblem, Bogart’s Kitchen, and Noon & Night, provide special solutions that are tailored to each type of patient or customer’s needs. This product line is designed to guarantee that patients with chronic illnesses receive care that is specially suited to meet their individual requirements.

Aleafia Health claims that its nationwide network of clinics and its substantial grassroots initiatives have made a big contribution to its success. They also keep people informed and safe by offering new patients free educational seminars on proper medical cannabis consumption. They also make sure that patients are matched to the most acceptable and effective medication.

The company also focuses on sustainability and its commitment to environmentally friendly practices. Aleafia is investing in sustainable cultivation methods and using renewable energy sources.

What plans does Aleafia Health have considering it’s investments in Europe?

Aleafia Health intends to lead the business in both countries and play a crucial role in the wider picture of a global presence by initially concentrating on Canada and eventually Germany, the largest and most lucrative medicinal marijuana markets in Europe. The European market is large and profitable but also subject to strict regulations, which the company has navigated successfully.

At the end of January 2023, Aleafia Health announced that it has signed a new European cannabis distribution partner. Thus, it is representing a one-year, approximately $1 million contract, significantly bolstering the Company’s record $1.2 million year-to-date sales in its growing international channel.

Now there is a high optimism about the company’s future prospects in the European medical cannabis market. The company’s efforts in the medical cannabis industry have positioned it as a player in the global cannabis market.


How Germany’s cannabis legalisation impacts other countries?

Alexandra Carstea: medical cannabis advocacy in Romania


Sustainability and growth in the hemp&cannabis industry: Synbiotic